Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4105388
Max Phase: Preclinical
Molecular Formula: C87H141N43O12
Molecular Weight: 1981.37
Molecule Type: Small molecule
Associated Items:
ID: ALA4105388
Max Phase: Preclinical
Molecular Formula: C87H141N43O12
Molecular Weight: 1981.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O
Standard InChI: InChI=1S/C87H141N43O12/c88-52(40-46-43-117-53-19-4-1-16-49(46)53)68(132)120-56(22-7-31-108-79(90)91)69(133)121-57(23-8-32-109-80(92)93)70(134)122-58(24-9-33-110-81(94)95)71(135)124-61(27-12-36-113-84(100)101)74(138)127-64(30-15-39-116-87(106)107)77(141)130-66(42-48-45-119-55-21-6-3-18-51(48)55)78(142)128-62(28-13-37-114-85(102)103)75(139)125-59(25-10-34-111-82(96)97)72(136)123-60(26-11-35-112-83(98)99)73(137)126-63(29-14-38-115-86(104)105)76(140)129-65(67(89)131)41-47-44-118-54-20-5-2-17-50(47)54/h1-6,16-21,43-45,52,56-66,117-119H,7-15,22-42,88H2,(H2,89,131)(H,120,132)(H,121,133)(H,122,134)(H,123,136)(H,124,135)(H,125,139)(H,126,137)(H,127,138)(H,128,142)(H,129,140)(H,130,141)(H4,90,91,108)(H4,92,93,109)(H4,94,95,110)(H4,96,97,111)(H4,98,99,112)(H4,100,101,113)(H4,102,103,114)(H4,104,105,115)(H4,106,107,116)/t52-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-/m0/s1
Standard InChI Key: CHFLHGYOXMUSHM-LLCHVMNLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1981.37 | Molecular Weight (Monoisotopic): 1980.1745 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Eksteen JJ, Ausbacher D, Simon-Santamaria J, Stiberg T, Cavalcanti-Jacobsen C, Wushur I, Svendsen JS, Rekdal Ø.. (2017) Iterative Design and in Vivo Evaluation of an Oncolytic Antilymphoma Peptide., 60 (1): [PMID:28004928] [10.1021/acs.jmedchem.6b00839] |
Source(1):